



Evidence reviews - December 2022

Evidence review

Published: 19 December 2022

www.nice.org.uk

The following documents contain the evidence that was used to develop the 2022 recommendations:

- [Ultrasound accuracy and threshold of nodule size and classification](#)
- [Indications for blood tests](#)
- [Radioisotope scan](#)
- [Diagnostic accuracy of fine needle aspiration cytology](#)
- [Efficacy of repeat fine needle aspiration cytology, active surveillance or discharge](#)
- [Molecular testing](#)
- [Imaging for further staging](#)
- [Initial treatments for differentiated thyroid cancer](#)
- [Thyrotropin alfa](#)
- [Radioactive iodine versus no radioactive iodine](#)
- [Activity of radioactive iodine after thyroidectomy](#)
- [External beam radiotherapy versus no external beam radiotherapy](#)
- [Thyroid stimulating hormone \(TSH\) suppression versus no TSH suppression](#)
- [Duration of thyroid stimulating hormone suppression](#)
- [Measurement of thyroglobulin](#)
- [Stimulated or highly sensitive thyroglobulin assays](#)
- [Length and frequency of follow up](#)
- [Information, education and support needed by people with suspected and confirmed thyroid cancer, and their families and carers](#)

Other supporting evidence

- [Methods](#)
- [Diagnostic economic analysis](#)
- [Thyroid stimulating hormone economic analysis](#)